Latest & greatest articles for calcium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on calcium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on calcium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for calcium

101. Apatite precipitation on a novel fast-setting calcium silicate cement containing fluoride (PubMed)

Apatite precipitation on a novel fast-setting calcium silicate cement containing fluoride Aim: Calcium silicate cements are widely used in endodontics. Novel fast-setting calcium silicate cement with fluoride (Protooth) has been developed for potential applications in teeth crowns including cavity lining and cementation. Objective: To evaluate the surface apatite-forming ability of Protooth compositions as a function of fluoride content and immersion time in phosphate-buffered saline (PBS (...) /belite Raman peak height indicated the apatite thickness. Results: Spherical calcium phosphate precipitations with acicular crystallites were formed after 1-day immersion in PBS and Raman spectra disclosed the phosphate band at 965 cm-1, supporting the apatite formation over Protooth compositions. The apatite deposition continued and more voluminous precipitations were observed after 56 days over the surface of all cements. Raman bands suggested the formation of β-type carbonated apatite over

Full Text available with Trip Pro

2016 Acta biomaterialia odontologica Scandinavica

102. NovaMin (Calcium Sodium Phosphosilicate) Dentifrices Reduce Dentinal Hypersensitivity More Than Potassium Nitrate Dentifrices

NovaMin (Calcium Sodium Phosphosilicate) Dentifrices Reduce Dentinal Hypersensitivity More Than Potassium Nitrate Dentifrices UTCAT3059, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title NovaMin (Calcium Sodium Phosphosilicate) Dentifrices Reduce Dentinal Hypersensitivity More Than Potassium Nitrate Dentifrices Clinical Question In healthy adult patients, do NovaMin dentifrices reduce symptoms of dentinal (...) -treatment data). A similar but longer trial might simulate real-world use of these products better. Applicability Dentinal hypersensitivity is a common condition, and many patients ask their dentist or hygienist for treatment recommendations. NovaMin and potassium nitrate are dentifrices that are applied in the same manner and provide a noninvasive treatment option for patients with dentinal hypersensitivity. The cost of NovaMin (calcium sodium phosphosilcate) dentifrices is slightly greater than

2016 UTHSCSA Dental School CAT Library

103. The Use of Casein Phosphopeptide Amorphous Calcium Phosphate Fluoride (CPP-ACPF) Products Can Improve The Salivary Rate And Buffer Capacity in Patients Undergoing Chemotherapy Treatment

The Use of Casein Phosphopeptide Amorphous Calcium Phosphate Fluoride (CPP-ACPF) Products Can Improve The Salivary Rate And Buffer Capacity in Patients Undergoing Chemotherapy Treatment UTCAT3013, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title The Use of Casein Phosphopeptide Amorphous Calcium Phosphate Fluoride (CPP-ACPF) Products Can Improve The Salivary Rate And Buffer Capacity in Patients Undergoing Chemotherapy (...) Treatment Clinical Question In patients undergoing chemotherapy, what is/are the effect(s) of casein phosphopeptide amorphous calcium phosphate fluoride (CPP-ACPF) products on oral and salivary status? Clinical Bottom Line For patients undergoing chemotherapy treatment, the application of casein phosphopeptide amorphous calcium phosphate fluoride (CPP-ACPF) paste twice daily can improve the resting & stimulated salivary rate and the buffering capacity. This finding is based on a randomized clinical

2016 UTHSCSA Dental School CAT Library

104. Calcium imaging and selective computed tomography angiography in comparison to functional testing for suspected coronary artery disease: the multicentre, randomized CRESCENT trial (PubMed)

Calcium imaging and selective computed tomography angiography in comparison to functional testing for suspected coronary artery disease: the multicentre, randomized CRESCENT trial To compare the effectiveness and safety of a cardiac computed tomography (CT) algorithm with functional testing in patients with symptoms suggestive of coronary artery disease (CAD).Between April 2011 and July 2013, 350 patients with stable angina, referred to the outpatient clinic of four Dutch hospitals, were (...) prospectively randomized between cardiac CT and functional testing (2 : 1 ratio). The tiered cardiac CT protocol included a calcium scan followed by CT angiography if the Agatston calcium score was between 1 and 400. Patients with test-specific contraindications were not excluded from study participation. By 1 year, fewer patients randomized to cardiac CT reported anginal complaints (P = 0.012). The cumulative radiation dose was slightly higher in the CT group (6.6 ± 8.7 vs. 6.1 ± 9.3 mSv; P < 0.0001

Full Text available with Trip Pro

2016 EvidenceUpdates Controlled trial quality: uncertain

105. Calcium channel blockers for primary Raynaud's phenomenon. (PubMed)

Calcium channel blockers for primary Raynaud's phenomenon. Calcium channel blockers are the most commonly prescribed drugs for people with primary Raynaud's phenomenon. Primary Raynaud's phenomenon is a common condition characterised by an exaggerated vasospastic response to cold or emotion: classically the digits (fingers and toes) turn white, then blue, then red. This is an update of the review first published in 2014.To assess the effects of different calcium channel blockers for primary (...) Raynaud's phenomenon as determined by attack rates, severity scores, participant-preference scores and physiological measurements.For this update the Cochrane Vascular Trial Search Co-ordinator searched the Specialised Register (last searched January 2016) and the Cochrane Register of Studies (CENTRAL) (2015, Issue 12). In addition the TSC searched clinical trials databases.Randomised controlled trials evaluating the effects of oral calcium channel blockers for the treatment of primary Raynaud's

Full Text available with Trip Pro

2016 Cochrane

106. The effect of casein phosphopeptide amorphous calcium phosphate fluoride paste (CPP-ACPF) on oral and salivary conditions of patients undergoing chemotherapy: A randomized controlled clinical trial. (PubMed)

The effect of casein phosphopeptide amorphous calcium phosphate fluoride paste (CPP-ACPF) on oral and salivary conditions of patients undergoing chemotherapy: A randomized controlled clinical trial. Oral and saliva conditions of patients undergoing chemotherapy is often affected by the medication they receive. Up to now, no appropriate medication that possesses the positive effects of chemotherapy without presenting oral complications has been introduced.The aim of this study was to assess

Full Text available with Trip Pro

2016 Electronic physician Controlled trial quality: uncertain

107. Electrophysiological properties and calcium handling of embryonic stem cell-derived cardiomyocytes (PubMed)

Electrophysiological properties and calcium handling of embryonic stem cell-derived cardiomyocytes Embryonic stem cell-derived cardiomyocytes (ESC-CMs) hold great interest in many fields of research including clinical applications such as stem cell and gene therapy for cardiac repair or regeneration. ESC-CMs are also used as a platform tool for pharmacological tests or for investigations of cardiac remodeling. ESC-CMs have many different aspects of morphology, electrophysiology, calcium

Full Text available with Trip Pro

2016 Integrative medicine research

108. 10-Year Coronary Heart Disease Risk Prediction Using Coronary Artery Calcium and Traditional Risk Factors: Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) With Validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Stu (PubMed)

10-Year Coronary Heart Disease Risk Prediction Using Coronary Artery Calcium and Traditional Risk Factors: Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) With Validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Stu Several studies have demonstrated the tremendous potential of using coronary artery calcium (CAC) in addition to traditional risk factors for coronary heart disease (CHD) risk prediction. However, to date, no risk score incorporating CAC has

Full Text available with Trip Pro

2015 EvidenceUpdates

109. Efficacy of nanocrystalline bone substitute biphasic calcium phosphate/poly-DL-lactide-co-glycolide for periodontal intrabony defects filling. (PubMed)

Efficacy of nanocrystalline bone substitute biphasic calcium phosphate/poly-DL-lactide-co-glycolide for periodontal intrabony defects filling. Different bone substitutes have been used for filling and reparation of intrabony defects. The aim of this study was to compare nanocrystalline material, biphasic calcium phosphate poly-DL-lactide-co-glycolide (BCP/PLGA) with deproteinised bovine bone (DPBB) and beta-tricalcium phosphate (P-TCP) in the treatment of periodontal intrabony defects.The study

2015 Vojnosanitetski pregled Controlled trial quality: uncertain

110. A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. (PubMed)

A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. Epidemiologic and preclinical data suggest that higher intake and serum levels of vitamin D and higher intake of calcium reduce the risk of colorectal neoplasia. To further study the chemopreventive potential of these nutrients, we conducted a randomized, double-blind, placebo-controlled trial of supplementation with vitamin D, calcium, or both for the prevention of colorectal adenomas.We recruited patients (...) with recently diagnosed adenomas and no known colorectal polyps remaining after complete colonoscopy. We randomly assigned 2259 participants to receive daily vitamin D3 (1000 IU), calcium as carbonate (1200 mg), both, or neither in a partial 2×2 factorial design. Women could elect to receive calcium plus random assignment to vitamin D or placebo. Follow-up colonoscopy was anticipated to be performed 3 or 5 years after the baseline examinations, according to the endoscopist's recommendation. The primary end

Full Text available with Trip Pro

2015 NEJM Controlled trial quality: predicted high

111. Reduced Risk of Parkinson's Disease in Users of Calcium Channel Blockers: A Meta-Analysis. (PubMed)

Reduced Risk of Parkinson's Disease in Users of Calcium Channel Blockers: A Meta-Analysis. Aim. To pool the data currently available to determine the association between calcium channel blockers (CCBs) and risk of Parkinson's disease (PD). Methods. Literature search in PubMed, EBSCO, and Cochrane library was undertaken through March 2014, looking for observational studies evaluating the association between CCBs use and PD. Pooled relative risk (RR) estimates and 95% confidence intervals (CIs (...) )); a significant heterogeneity was found between studies (P = 0.031; I (2) 54.6%). Both the classes of CCB, that is, dihydropyridine calcium channel blockers (DiCCB) (0.80 (95% CI, 0.65-0.98) P = 0.032) and non-DiCCB (0.70 (95% CI, 0.53-0.92) P = 0.013), were found to be reducing the risk of PD. Conclusion. In our analysis, we found that CCBs use was associated with a Significantly decreased risk of PD compared with non-CCB use.

Full Text available with Trip Pro

2015 International journal of chronic diseases

112. Routine administration of intravenous calcium during exchange blood transfusion for treatment of severe neonatal hyperbilirubinaemia: a systematic review of quantitative evidence. (PubMed)

Routine administration of intravenous calcium during exchange blood transfusion for treatment of severe neonatal hyperbilirubinaemia: a systematic review of quantitative evidence. The objective of this review is to assess the effectiveness of intravenous calcium given during exchange blood transfusion (EBT) in neonates.More specifically, the objectives of the review are to determine whether:Neonatal hyperbilirubinaemia is an abnormally high level of bilirubin in the circulating blood, resulting (...) be quite ineffective in resource limited settings where the required facilities and electrical power supply are inadequate. Under these circumstances neonates with severe hyperbilirubinaemia will most likely be treated with EBT.Exchange transfusion of blood collected with acid-citrate-dextrose (ACD) containing bags may produce hypocalcaemia.To decrease the morbidity from chelation of divalent cations by citrate, routine administration of calcium gluconate during EBT was advocated,but tetany, convulsion

2015 JBI database of systematic reviews and implementation reports

113. Citrate salts for preventing and treating calcium containing kidney stones in adults. (PubMed)

Citrate salts for preventing and treating calcium containing kidney stones in adults. Kidney stones affect people worldwide and have a high rate of recurrence even with treatment. Recurrences are particularly prevalent in people with low urinary citrate levels. These people have a higher incidence of calcium phosphate and calcium oxalate stones. Oral citrate therapy increases the urinary citrate levels, which in turn binds with calcium and inhibits the crystallisation thus reduces stone (...) formation. Despite the widespread use of oral citrate therapy for prevention and treatment of calcium oxalate stones, the evidence to support its clinical efficacy remains uncertain.The objective of this review was to determine the efficacy and adverse events associated with citrate salts for the treatment and prevention of calcium containing kidney stones.We searched the Cochrane Kidney and Transplant Specialised Register to 29 July 2015 through contact with the Trials' Search Co-ordinator using search

Full Text available with Trip Pro

2015 Cochrane

114. Calcium channel blockers for pulmonary arterial hypertension. (PubMed)

Calcium channel blockers for pulmonary arterial hypertension. Pulmonary arterial hypertension (PAH) is one of several forms of pulmonary hypertension: a chronic disease of the pulmonary vasculature. The mean age at diagnosis is around 50 years old, with increasing prevalence in people over 70 years old (10% to 17%). The median survival to be approximately seven years with one-, three-, five-, and seven-year survival rates from time of diagnostic right-sided heart catheterization were 85%, 68 (...) %, 57%, and 49%, respectively. Several studies showed that calcium channel blockers (CCBs) reduce right ventricular hypertrophy and improve long-term haemodynamics in PAH.To evaluate the clinical efficacy and harms of CCBs for people with PAH.The search strategy was provided by the Cochrane Airways Group Trials Search Co-ordinator. The following databases were searched from their inception until September 2014: the Cochrane Airways Group Register of Trials (CAGR); the Cochrane Central Register

Full Text available with Trip Pro

2015 Cochrane

115. Is Shock Index a Valid Predictor of Mortality in Emergency Department Patients With Hypertension, Diabetes, High Age, or Receipt of beta- or Calcium Channel Blockers? (PubMed)

Is Shock Index a Valid Predictor of Mortality in Emergency Department Patients With Hypertension, Diabetes, High Age, or Receipt of beta- or Calcium Channel Blockers? Shock index is a widely reported tool to identify patients at risk for circulatory collapse. We hypothesize that old age, diabetes, hypertension, and β- or calcium channel blockers weaken the association between shock index and mortality.This was a cohort study of all first-time emergency department (ED) visits between 1995 (...) and 2011 (n=111,019). We examined whether age 65 years or older, diabetes, hypertension, and use of β- or calcium channel blockers modified the association between shock index and 30-day mortality.The 30-day mortality was 3.0%. For all patients, with shock index less than 0.7 as reference, a shock index of 0.7 to 1 had an adjusted odds ratio (OR) of 2.9 (95% confidence interval [CI] 2.7 to 3.2) for 30-day mortality, whereas shock index greater than or equal to 1 had an OR of 10.5 (95% CI 9.3 to 11.7

2015 EvidenceUpdates

116. Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker (nifedipine) and an alpha-blocker (tam

Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker (nifedipine) and an alpha-blocker (tam Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker (nifedipine) and an alpha

2015 NIHR HTA programme

117. Calcium supplementation for prevention of primary hypertension. (PubMed)

Calcium supplementation for prevention of primary hypertension. Hypertension is a major public health problem that increases the risk of cardiovascular and kidney diseases. Several studies have shown an inverse association between calcium intake and blood pressure. As small reductions in blood pressure have been shown to produce rapid reductions in vascular disease risk even in individuals with normal blood pressure ranges, this review intends to evaluate the effect of calcium supplementation (...) in normotensive individuals as a preventive health measure.To assess the efficacy and safety of calcium supplementation versus placebo or control for reducing blood pressure in normotensive people.We searched the Cochrane Hypertension Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In-Process, EMBASE and ClinicalTrials.gov for randomised controlled trials up to October 2014. The WHO International Clinical Trials Registry Platform (ICTRP) is searched

Full Text available with Trip Pro

2015 Cochrane

118. Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial. (PubMed)

Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial. Antiretroviral therapy initiation for HIV-1 infection is associated with 2% to 6% loss of bone mineral density (BMD).To evaluate the effect of vitamin D3 plus calcium supplementation on bone loss associated with antiretroviral therapy initiation.48-week prospective, randomized, double-blind, placebo-controlled study. (ClinicalTrials.gov: NCT01403051).39 AIDS Clinical Trials Group units.Adults (...) with antiretroviral therapy-naive HIV.BMD by dual-energy x-ray absorptiometry, 25-hydroxyvitamin D levels, and other laboratory assessments.165 eligible patients were randomly assigned (79 received vitamin D3 plus calcium and 86 received placebo). The study groups were well-balanced at baseline: 90% were men, 33% were non-Hispanic black, and the median CD4 count was 0.341 × 109 cells/L. At 48 weeks, the percentage of decline in total hip BMD was smaller in the vitamin D3 plus calcium group than in the placebo

Full Text available with Trip Pro

2015 Annals of Internal Medicine Controlled trial quality: predicted high

119. Long-term Use of Acamprosate Calcium for Alcoholism

Long-term Use of Acamprosate Calcium for Alcoholism Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other (...) not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners? own terms and conditions. TITLE: Long-term Use of Acamprosate Calcium for Alcoholism: A Review of the Clinical

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

120. High-Protein Diet Without Increased Calcium Intake Can Lead to Ridge Resorption and Osteoporosis in Women

High-Protein Diet Without Increased Calcium Intake Can Lead to Ridge Resorption and Osteoporosis in Women UTCAT2893, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title High-Protein Diet Without Increased Calcium Intake Can Lead to Ridge Resorption and Osteoporosis in Women Clinical Question How does a high protein diet affect ridge resorption in women? Clinical Bottom Line A high protein diet coupled with a low calcium (...) intake can increase urinary losses of calcium and is linked to osteoporosis and ridge resorption in older women. This is supported by narrative reviews outlining observations of populations who maintain a high protein diet and a narrative review of studies showing the relationship between increased protein intake and increased levels of calcium lost in urine. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence

2015 UTHSCSA Dental School CAT Library